Receive our newsletter – data, insights and analysis delivered to you
July 8, 2009

Novartis’ Rasilez to be Available in Japan

Novartis' high blood pressure medicine Rasilez (aliskiren) will become available in Japan after the drug received approval from the Japanese health department. Rasilez directly inhibits renin, an enzyme that triggers a process leading to high blood pressure and organ damage. The

By cms admin

Novartis’ high blood pressure medicine Rasilez (aliskiren) will become available in Japan after the drug received approval from the Japanese health department.

Rasilez directly inhibits renin, an enzyme that triggers a process leading to high blood pressure and organ damage.

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Rasilez for the treatment of high blood pressure, alone or in combination with other high blood pressure medicines.

The potential long-term benefits of Rasilez are still being investigated in the ASPIRE HIGHER programme, which involves more than 35,000 patients in 14 trials.

Novartis global head of development Trevor Mundel said that the company was excited about the approval in Japan.

“This provides Japanese patients with access to this innovative high blood pressure treatment that directly targets rennin,” Mundel said.

Rasilez, also known as Tekturna, has been approved in over 70 countries.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU